Even though there is high concordance between CSF and [18-F]AV1451 measures, CSF p-tau abnormality seems to precede [18-F]AV1451 PET tau positivity and marks the early stages of underlying AD pathology (49). The gene discussed is MAPT; the disease is Alzheimer disease.